UTHR vs. BMRN, IONS, ALNY, MDGL, ALKS, RDY, SRPT, VTRS, CTLT, and ROIV
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Viatris (VTRS), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics (NASDAQ:UTHR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking.
94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 12.5% of United Therapeutics shares are held by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioMarin Pharmaceutical received 966 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 74.70% of users gave BioMarin Pharmaceutical an outperform vote while only 61.71% of users gave United Therapeutics an outperform vote.
United Therapeutics has a net margin of 42.05% compared to BioMarin Pharmaceutical's net margin of 8.31%. United Therapeutics' return on equity of 18.72% beat BioMarin Pharmaceutical's return on equity.
United Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
In the previous week, BioMarin Pharmaceutical had 19 more articles in the media than United Therapeutics. MarketBeat recorded 33 mentions for BioMarin Pharmaceutical and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.88 beat BioMarin Pharmaceutical's score of 0.27 indicating that United Therapeutics is being referred to more favorably in the media.
United Therapeutics currently has a consensus price target of $308.78, suggesting a potential upside of 12.59%. BioMarin Pharmaceutical has a consensus price target of $106.11, suggesting a potential upside of 36.80%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.
United Therapeutics has higher revenue and earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
United Therapeutics beats BioMarin Pharmaceutical on 10 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
